PROPHASE LABS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.71 USD | -4.85% |
|
-10.46% | +4.20% |
| Apr. 16 | Health Care Ticks Up After UnitedHealth Earnings -- Health Care Roundup | DJ |
| Apr. 16 | ProPhase Labs, Inc. Unveils Project ZenQ-AI | CI |
Presentation Operator MessageOperator (Operator)Good day, and welcome to the ProPhase Labs Sec...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
ProPhase Labs, Inc. is a biopharma, genomics, and diagnostics company. The Company provides whole genome sequencing solutions, while developing potential diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. Its segments include diagnostic services and consumer products. The diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third party payers and government organizations. The consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of over-the-counter consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services. Its CLIA labs and diagnostic technology provide wellness solutions.
Calendar
2024-05-01
- Planet MicroCap Showcase
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +4.20% | 84.99M | |
| -16.58% | 8.25B | |
| +39.20% | 3.58B | |
| -39.11% | 2.46B | |
| -8.06% | 2.46B | |
| -6.70% | 2.38B | |
| -19.01% | 1.55B | |
| -40.66% | 1.21B | |
| +7.56% | 1.11B | |
| -14.57% | 1.03B |
- Stock Market
- Equities
- PRPH Stock
- News ProPhase Labs, Inc.
- Transcript : ProPhase Labs, Inc., Q2 2023 Earnings Call, Aug 10, 2023
